Invitris

Invitris is revolutionizing the creation of innovative biological drugs. Their patent-pending technology platform facilitates the transformation of DNA into synthetic proteins, a process recently highlighted in Science magazine. This groundbreaking approach dramatically enhances drug creation efficiency by over 10,000 times, while simultaneously reducing material costs by more than 100-fold. The company's primary application focuses on developing synthetic bacteriophages to address the growing threat of antibiotic-resistant infections, a crisis projected to surpass cancer as a leading cause of mortality. Invitris is poised to make a significant impact on global healthcare by accelerating drug discovery and development.